Brief: Paxman Opens Cipn Clinical Trial With National University Hospital, Singapore

Paxman AB (publ)

04/11/2021 14:11

Nov 4 (Reuters) - Paxman AB (publ)  PAX.ST :
    * OPENS CIPN CLINICAL TRIAL WITH NATIONAL UNIVERSITY HOSPITAL, SINGAPORE
    * STUDY IS ESTIMATED TO START THIS MONTH WITH COMPLETION DATE ESTIMATED TO BE SEPTEMBER 2023
    * STUDY AIMS TO INVESTIGATE SAFETY AND TOLERABILITY OF LIMB CRYOCOMPRESSION IN PREVENTING OF
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) VIA NEWLY DEVELOPED PAXMAN CRYOCOMPRESSION
SYSTEM (PCCS) IN HEALTHY SUBJECTS AND CANCER PATIENTS
    * LARGER RANDOMIZED PHASE 3 EFFICACY STUDY IS BEING PLANNED TO BE OPENED IN SECOND HALF OF
2022
    * PAXMAN DEVICE WILL BE TESTED FOR ITS SAFETY IN DELIVERING LIMB CRYOCOMPRESSION AND
EFFICACY IN
IMPROVING PRESERVATION OF PERIPHERAL NERVES DURING CHEMOTHERAPY

Source text for Eikon:  ID:nMFN9ZGmVv 
Further company coverage:  PAX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))